Magnetic Nanoparticle and Magnetic Field Assisted siRNA Delivery In Vitro

  • Olga Mykhaylyk
  • Yolanda Sanchez-Antequera
  • Dialechti Vlaskou
  • Maria Belen Cerda
  • Mehrdad Bokharaei
  • Edelburga Hammerschmid
  • Martina Anton
  • Christian Plank
Part of the Methods in Molecular Biology book series (MIMB, volume 1218)


This chapter describes how to design and conduct experiments to deliver siRNA to adherent cell cultures in vitro by magnetic force-assisted transfection using self-assembled complexes of small interfering RNA (siRNA) and cationic lipids or polymers that are associated with magnetic nanoparticles (MNPs). These magnetic complexes are targeted to the cell surface by the application of a gradient magnetic field. A further development of the magnetic drug-targeting concept is combining it with an ultrasound-triggered delivery using magnetic microbubbles as a carrier for gene or drug delivery. For this purpose, selected MNPs, phospholipids, and siRNAs are assembled in the presence of perfluorocarbon gas into flexible formulations of magnetic lipospheres (microbubbles). Methods are described how to accomplish the synthesis of magnetic nanoparticles for magnetofection and how to test the association of siRNA with the magnetic components of the transfection vector. A simple method is described to evaluate magnetic responsiveness of the magnetic siRNA transfection complexes and estimate the complex loading with magnetic nanoparticles. Procedures are provided for the preparation of magnetic lipoplexes and polyplexes of siRNA as well as magnetic microbubbles for magnetofection and downregulation of the target gene expression analysis with account for the toxicity determined using an MTT-based respiration activity test. A modification of the magnetic transfection triplexes with INF-7, fusogenic peptide, is described resulting in reporter gene silencing improvement in HeLa, Caco-2, and ARPE-19 cells. The methods described can also be useful for screening vector compositions and novel magnetic nanoparticle preparations for optimized siRNA transfection by magnetofection in any cell type.

Key words

siRNA delivery in vitro Magnetic nanoparticles Magnetic transfection vectors Microbubble Sonoporation 



We gratefully acknowledge the support from the German Research Foundation through the DFG Research Unit FOR917 (Project PL 281/3-1), from the German Federal Ministry of Education and Research through grants ZIM-KOOP “STEP-MAG,” Nanobiotechnology grants 13N8186 and 13N8538, and from the Excellence Cluster “Nanosystems Initiative Munich.” The authors would like to thank Dr. Bob Scholte for transduction of the H441 cells with eGFP and luciferase using lentiviral vectors and Dr. Christian Bergemann (chemicell GmbH, Berlin) for providing MNPs for the preparation of the MAALs. This work was supported by the European Union through the FP6-LIFESCIHEALTH Project “Improved precision of nucleic acid based therapy of cystic fibrosis” under contract no. 005213.


  1. 1.
    Plank C, Scherer F, Schillinger U, Anton M (2000) Magnetofection: enhancement and localization of gene delivery with magnetic particles under the influence of a magnetic field. J Gene Med 2(Suppl):24Google Scholar
  2. 2.
    Mah C, Zolotukhin I, Fraites TJ, Dobson J, Batich C, Byrne BJ (2000) Microsphere-mediated delivery of recombinant AAV vectors in vitro and in vivo. Mol Ther 1:S239CrossRefGoogle Scholar
  3. 3.
    Scherer F, Anton M, Schillinger U, Henke J, Bergemann C, Kruger A, Gansbacher B, Plank C (2002) Magnetofection: enhancing and targeting gene delivery by magnetic force in vitro and in vivo. Gene Ther 9:102–109PubMedCrossRefGoogle Scholar
  4. 4.
    Pandori M, Hobson D, Sano T (2002) Adenovirus-microbead conjugates possess enhanced infectivity: a new strategy for localized gene delivery. Virology 299:204–212PubMedCrossRefGoogle Scholar
  5. 5.
    Mah C, Fraites TJ Jr, Zolotukhin I, Song S, Flotte TR, Dobson J, Batich C, Byrne BJ (2002) Improved method of recombinant AAV2 delivery for systemic targeted gene therapy. Mol Ther 6:106–112PubMedCrossRefGoogle Scholar
  6. 6.
    Hughes C, Galea-Lauri J, Farzaneh F, Darling D (2001) Streptavidin paramagnetic particles provide a choice of three affinity-based capture and magnetic concentration strategies for retroviral vectors. Mol Ther 3:623–630PubMedCrossRefGoogle Scholar
  7. 7.
    Plank C, Anton M, Rudolph C, Rosenecker J, Krotz F (2003) Enhancing and targeting nucleic acid delivery by magnetic force. Expert Opin Biol Ther 3:745–758PubMedCrossRefGoogle Scholar
  8. 8.
    Plank C, Zelphati O, Mykhaylyk O (2011) Magnetically enhanced nucleic acid delivery. Ten years of magnetofection-progress and prospects. Adv Drug Deliv Rev 63:1300–1331PubMedCrossRefGoogle Scholar
  9. 9.
    Schillinger U, Brill T, Rudolph C, Huth S, Gersting S, Krotz F, Hirschberger J, Bergemann C, Plank C (2005) Advances in magnetofection - magnetically guided nucleic acid delivery. J Magn Magn Mater 293:501–508CrossRefGoogle Scholar
  10. 10.
    Huth S, Lausier J, Gersting SW, Rudolph C, Plank C, Welsch U, Rosenecker J (2004) Insights into the mechanism of magnetofection using PEI-based magnetofectins for gene transfer. J Gene Med 6:923–936PubMedCrossRefGoogle Scholar
  11. 11.
    Krotz F, de Wit C, Sohn HY, Zahler S, Gloe T, Pohl U, Plank C (2003) Magnetofection–a highly efficient tool for antisense oligonucleotide delivery in vitro and in vivo. Mol Ther 7:700–710PubMedCrossRefGoogle Scholar
  12. 12.
    Sauer AM, de Bruin KG, Ruthardt N, Mykhaylyk O, Plank C, Brauchle C (2009) Dynamics of magnetic lipoplexes studied by single particle tracking in living cells. J Control Release 137:136–145PubMedCrossRefGoogle Scholar
  13. 13.
    Plank C, Schillinger U, Scherer F, Bergemann C, Remy JS, Krotz F, Anton M, Lausier J, Rosenecker J (2003) The magnetofection method: using magnetic force to enhance gene delivery. Biol Chem 384:737–747PubMedCrossRefGoogle Scholar
  14. 14.
    Dobson J (2006) Gene therapy progress and prospects: magnetic nanoparticle-based gene delivery. Gene Ther 13:283–287PubMedCrossRefGoogle Scholar
  15. 15.
    Doshida M, Ohmichi M, Tsutsumi S, Kawagoe J, Takahashi T, Du B, Mori-Abe A, Ohta T, Saitoh-Sekiguchi M, Takahashi K et al (2006) Raloxifene increases proliferation and up-regulates telomerase activity in human umbilical vein endothelial cells. J Biol Chem 281:24270–24278PubMedCrossRefGoogle Scholar
  16. 16.
    Deleuze V, Chalhoub E, El-Hajj R, Dohet C, Le Clech M, Couraud PO, Huber P, Mathieu D (2007) TAL-1/SCL and its partners E47 and LMO2 up-regulate VE-cadherin expression in endothelial cells. Mol Cell Biol 27:2687–2697PubMedPubMedCentralCrossRefGoogle Scholar
  17. 17.
    McCaig C, Duval C, Hemers E, Steele I, Pritchard DM, Przemeck S, Dimaline R, Ahmed S, Bodger K, Kerrigan DD et al (2006) The role of matrix metalloproteinase-7 in redefining the gastric microenvironment in response to Helicobacter pylori. Gastroenterology 130:1754–1763PubMedCrossRefGoogle Scholar
  18. 18.
    Uchida Y, Ohshima T, Sasaki Y, Suzuki H, Yanai S, Yamashita N, Nakamura F, Takei K, Ihara Y, Mikoshiba K et al (2005) Semaphorin3A signalling is mediated via sequential Cdk5 and GSK3beta phosphorylation of CRMP2: implication of common phosphorylating mechanism underlying axon guidance and Alzheimer's disease. Genes Cells 10:165–179PubMedCrossRefGoogle Scholar
  19. 19.
    Huang P, Senga T, Hamaguchi M (2007) A novel role of phospho-beta-catenin in microtubule regrowth at centrosome. Oncogene 26:4357–4371PubMedCrossRefGoogle Scholar
  20. 20.
    Sapet C, Simoncini S, Loriod B, Puthier D, Sampol J, Nguyen C, Dignat-George F, Anfosso F (2006) Thrombin-induced endothelial microparticle generation: identification of a novel pathway involving ROCK-II activation by caspase-2. Blood 108:1868–1876PubMedCrossRefGoogle Scholar
  21. 21.
    Minami R, Yamamoto M, Takahama S, Miyamura T, Watanabe H, Suematsu E (2006) RCAS1 induced by HIV-Tat is involved in the apoptosis of HIV-1 infected and uninfected CD4+ T cells. Cell Immunol 243:41–47PubMedCrossRefGoogle Scholar
  22. 22.
    Simoncini S, Njock MS, Robert S, Camoin-Jau L, Sampol J, Harle JR, Nguyen C, Dignat-George F, Anfosso F (2009) TRAIL/Apo2L mediates the release of procoagulant endothelial microparticles induced by thrombin in vitro: a potential mechanism linking inflammation and coagulation. Circ Res 104:943–951PubMedCrossRefGoogle Scholar
  23. 23.
    Meda C, Plank C, Mykhaylyk O, Schmidt K, Mayer B (2010) Effects of statins on nitric oxide/cGMP signaling in human umbilical vein endothelial cells. Pharmacol Rep 62:100–112PubMedCrossRefGoogle Scholar
  24. 24.
    Melki MT, Saidi H, Dufour A, Olivo-Marin JC, Gougeon ML (2010) Escape of HIV-1-infected dendritic cells from TRAIL-mediated NK cell cytotoxicity during NK-DC cross-talk–a pivotal role of HMGB1. PLoS Pathog 6:e1000862PubMedPubMedCentralCrossRefGoogle Scholar
  25. 25.
    Tajika Y, Takahashi M, Hino M, Murakami T, Yorifuji H (2010) VAMP2 marks quiescent satellite cells and myotubes, but not activated myoblasts. Acta Histochem Cytochem 43:107–114PubMedPubMedCentralCrossRefGoogle Scholar
  26. 26.
    Namiki Y, Namiki T, Yoshida H, Ishii Y, Tsubota A, Koido S, Nariai K, Mitsunaga M, Yanagisawa S, Kashiwagi H et al (2009) A novel magnetic crystal-lipid nanostructure for magnetically guided in vivo gene delivery. Nat Nanotechnol 4:598–606PubMedCrossRefGoogle Scholar
  27. 27.
    Zhang H, Lee MY, Hogg MG, Dordick JS, Sharfstein ST (2010) Gene delivery in three-dimensional cell cultures by superparamagnetic nanoparticles. ACS Nano 4:4733–4743PubMedCrossRefGoogle Scholar
  28. 28.
    Bonetta L (2005) The inside scoop - evaluating gene delivery methods. Nat Methods 2:875–883CrossRefGoogle Scholar
  29. 29.
    Smith C (2006) Sharpening the tools of RNA interference. Nat Methods 3:475–486CrossRefGoogle Scholar
  30. 30.
    Booth BA, Vidal Denham L, Bouhanik S, Jacob JT, Hill JM (2007) Sustained-release ophthalmic drug delivery systems for treatment of macular disorders: present and future applications. Drugs Aging 24:581–602PubMedCrossRefGoogle Scholar
  31. 31.
    Lee SS, Michael R (2009) Novel drug delivery systems for retinal diseases. Ophthalmic Res 41:124–135PubMedCrossRefGoogle Scholar
  32. 32.
    Vlaskou D, Mykhaylyk O, Krötz F, Hellwig N, Renner R, Schillinger U, Gleich B, Heidsieck A, Schmitz G, Hensel K et al (2010) Magnetic and acoustically active lipospheres for magnetically targeted nucleic acid delivery. Adv Funct Mater 20:3881–3894Google Scholar
  33. 33.
    Lee SS, Robinson MR (2009) Novel drug delivery systems for retinal diseases. A review. Ophthalmic Res 41:124–135PubMedCrossRefGoogle Scholar
  34. 34.
    Myles ME, Neumann DM, Hill JM (2005) Recent progress in ocular drug delivery for posterior segment disease: emphasis on transscleral iontophoresis. Adv Drug Deliv Rev 57:2063–2079PubMedCrossRefGoogle Scholar
  35. 35.
    Yasukawa T, Ogura Y, Tabata Y, Kimura H, Wiedemann P, Honda Y (2004) Drug delivery systems for vitreoretinal diseases. Prog Retin Eye Res 23:253–281PubMedCrossRefGoogle Scholar
  36. 36.
    Pavan PR, Burrows A, Pavan-LAngston D (2008) Retina and vitreous, 2008th edn. Lippincott Williams & Wilkins, PhiladelphiaGoogle Scholar
  37. 37.
    Jager RD, Aiello LP, Patel SC, Cunningham ET Jr (2004) Risks of intravitreous injection: a comprehensive review. Retina 24:676–698PubMedCrossRefGoogle Scholar
  38. 38.
    Liu MM, Tuo J, Chan CC (2011) Gene therapy for ocular diseases. Br J Ophthalmol 95:604–612PubMedPubMedCentralCrossRefGoogle Scholar
  39. 39.
    Gaudana R, Jwala J, Boddu SH, Mitra AK (2009) Recent perspectives in ocular drug delivery. Pharm Res 26:1197–1216PubMedCrossRefGoogle Scholar
  40. 40.
    Bloquel C, Bourges JL, Touchard E, Berdugo M, BenEzra D, Behar-Cohen F (2006) Non-viral ocular gene therapy: potential ocular therapeutic avenues. Adv Drug Deliv Rev 58:1224–1242PubMedCrossRefGoogle Scholar
  41. 41.
    Fechheimer M, Boylan JF, Parker S, Sisken JE, Patel GL, Zimmer SG (1987) Transfection of mammalian cells with plasmid DNA by scrape loading and sonication loading. Proc Natl Acad Sci U S A 84:8463–8467PubMedPubMedCentralCrossRefGoogle Scholar
  42. 42.
    Kim HJ, Greenleaf JF, Kinnick RR, Bronk JT, Bolander ME (1996) Ultrasound-mediated transfection of mammalian cells. Hum Gene Ther 7:1339–1346PubMedCrossRefGoogle Scholar
  43. 43.
    Bao SP, Thrall BD, Miller DL (1997) Transfection of a reporter plasmid into cultured cells by sonoporation in vitro. Ultrasound Med Biol 23:953–959PubMedCrossRefGoogle Scholar
  44. 44.
    Newman CM, Lawrie A, Brisken AF, Cumberland DC (2001) Ultrasound gene therapy: on the road from concept to reality. Echocardiography 18:339–347PubMedCrossRefGoogle Scholar
  45. 45.
    Tata DB, Dunn F, Tindall DJ (1997) Selective clinical ultrasound signals mediate differential gene transfer and expression in two human prostate cancer cell lines: LnCap and PC-3. Biochem Biophys Res Commun 234:64–67PubMedCrossRefGoogle Scholar
  46. 46.
    Lawrie A, Brisken AF, Francis SE, Tayler DI, Chamberlain J, Crossman DC, Cumberland DC, Newman CM (1999) Ultrasound enhances reporter gene expression after transfection of vascular cells in vitro. Circulation 99:2617–2620PubMedCrossRefGoogle Scholar
  47. 47.
    Hernot S, Klibanov AL (2008) Microbubbles in ultrasound-triggered drug and gene delivery. Adv Drug Deliv Rev 60:1153–1166PubMedPubMedCentralCrossRefGoogle Scholar
  48. 48.
    Vlaskou D, Pradhan P, Bergemann C, Klibanov AL, Hensel K, Schmitz G, Plank C, Mykhaylyk O (2010) Magnetic microbubbles: magnetically targeted and ultrasound-triggered vectors for gene delivery in vitro. AIP Conf Proc 1311:485–494CrossRefGoogle Scholar
  49. 49.
    Plank C, Scherer F, Rudolph C (2005). Localized nucleic acid delivery: A discussion of selected methods. In Schleef M (ed), DNA pharmaceuticals. Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim, p. 55–116Google Scholar
  50. 50.
    Hellwig N, Plank C, Vlaskou D, Bridell H, Sohn HY, Pohl U, Krotz F (2005) Ultrasound-enhanced microbubble-magnetofection: a new approach for targeted delivery of nucleotides in vivo. J Vasc Res 42:86–87Google Scholar
  51. 51.
    Vlaskou D, Mykhaylyk O, Giunta R, Neshkova I, Hellwig N, Kroetz F, Bergemann C, Plank C (2006) Magnetic microbubbles: new carriers for localized gene and drug delivery. Mol Ther 13:S290CrossRefGoogle Scholar
  52. 52.
    del Pino P, Munoz-Javier A, Vlaskou D, Rivera Gil P, Plank C, Parak WJ (2010) Gene silencing mediated by magnetic lipospheres tagged with small interfering RNA. Nano Lett 10:3914–3921PubMedCrossRefGoogle Scholar
  53. 53.
    Holzbach T, Vlaskou D, Neshkova I, Konerding MA, Wortler K, Mykhaylyk O, Gansbacher B, Machens HG, Plank C, Giunta RE (2010) Non-viral VEGF(165) gene therapy - magnetofection of acoustically active magnetic lipospheres ('magnetobubbles') increases tissue survival in an oversized skin flap model. J Cell Mol Med 14:587–599PubMedGoogle Scholar
  54. 54.
    Unger EC, McCreery TP, Sweitzer RH, Caldwell VE, Wu Y (1998) Acoustically active lipospheres containing paclitaxel: a new therapeutic ultrasound contrast agent. Invest Radiol 33:886–892PubMedCrossRefGoogle Scholar
  55. 55.
    Stride E, Porter C, Prieto AG, Pankhurst Q (2009) Enhancement of microbubble mediated gene delivery by simultaneous exposure to ultrasonic and magnetic fields. Ultrasound Med Biol 35:861–868PubMedCrossRefGoogle Scholar
  56. 56.
    Lentacker I, De Smedt S, Demeester J, Van Marck V, Bracke M, Sanders N (2007) Lipoplex-loaded microbubbles for gene delivery: a trojan horse controlled by ultrasound. Hum Gene Ther 18:1046–1046Google Scholar
  57. 57.
    Felgner PL, Barenholz Y, Behr JP, Cheng SH, Cullis P, Huang L, Jessee JA, Seymour L, Szoka F, Thierry AR et al (1997) Nomenclature for synthetic gene delivery systems. Hum Gene Ther 8:511–512PubMedCrossRefGoogle Scholar
  58. 58.
    Mykhaylyk O, Vlaskou D, Tresilwised N, Pithayanukul P, Moller W, Plank C (2007) Magnetic nanoparticle formulations for DNA and siRNA delivery. J Magn Magn Mater 311:275–281CrossRefGoogle Scholar
  59. 59.
    Mykhaylyk O, Sobisch T, Almstatter I, Sanchez-Antequera Y, Brandt S, Anton M, Doblinger M, Eberbeck D, Settles M, Braren R et al (2012) Silica-iron oxide magnetic nanoparticles modified for gene delivery: a search for optimum and quantitative criteria. Pharm Res 29:1344–1365PubMedCrossRefGoogle Scholar
  60. 60.
    Terebesi J, Kwok KY, Rice KG (1998) Iodinated plasmid DNA as a tool for studying gene delivery. Anal Biochem 263:120–123PubMedCrossRefGoogle Scholar
  61. 61.
    Azzam T, Domb AJ (2004) Current developments in gene transfection agents. Curr Drug Deliv 1:165–193PubMedCrossRefGoogle Scholar
  62. 62.
    Landschulz W, Thesleff I, Ekblom P (1984) A lipophilic iron chelator can replace transferrin as a stimulator of cell-proliferation and differentiation. J Cell Biol 98:596–601PubMedCrossRefGoogle Scholar
  63. 63.
    Kovar J (1990) Insoluble iron compound is able to stimulate growth of cultured-cells. In Vitro Cell Dev Biol 26:1026–1027PubMedCrossRefGoogle Scholar
  64. 64.
    Savonniere S, Zeghari N, Miccoli L, Muller S, Maugras M, Donner M (1996) Effects of lipid supplementation of culture media on cell growth, antibody production, membrane structure and dynamics in two hybridomas. J Biotechnol 48:161–173PubMedCrossRefGoogle Scholar
  65. 65.
    Plank C, Oberhauser B, Mechtler K, Koch C, Wagner E (1994) The influence of endosome-disruptive peptides on gene-transfer using synthetic virus-like gene-transfer systems. J Biol Chem 269:12918–12924PubMedGoogle Scholar
  66. 66.
    Plank C, Zauner W, Wagner E (1998) Application of membrane-active peptides for drug and gene delivery across cellular membranes. Adv Drug Deliv Rev 34:21–35PubMedCrossRefGoogle Scholar
  67. 67.
    Funhoff AM, van Nostrum CF, Lok MC, Fretz MM, Crommelin DJ, Hennink WE (2004) Poly(3-guanidinopropyl methacrylate): a novel cationic polymer for gene delivery. Bioconjug Chem 15:1212–1220PubMedCrossRefGoogle Scholar
  68. 68.
    Jiang X, Lok MC, Hennink WE (2007) Degradable-brushed pHEMA-pDMAEMA synthesized via ATRP and click chemistry for gene delivery. Bioconjug Chem 18:2077–2084PubMedCrossRefGoogle Scholar
  69. 69.
    Oliveira S, van Rooy I, Kranenburg O, Storm G, Schiffelers RM (2007) Fusogenic peptides enhance endosomal escape improving siRNA-induced silencing of oncogenes. Int J Pharm 331:211–214PubMedCrossRefGoogle Scholar
  70. 70.
    Kowalskia JB, Tallentireb A (1999) Substantiation of 25 kGy as a sterilization dose: a rational approach to establishing verification dose. Radiat Phys Chem 54:55–64CrossRefGoogle Scholar
  71. 71.
    von Gersdorff K (2006) PEG-shielded and egf receptor-targeted dna polyplexes: cellular mechanisms. Doctor Thesis. München 1–125Google Scholar
  72. 72.
    Berridge MV, Herst PM, Tan AS (2005) Tetrazolium dyes as tools in cell biology: new insights into their cellular reduction. Biotechnol Annu Rev 11:127–152PubMedCrossRefGoogle Scholar
  73. 73.
    Berridge MV, Tan AS, Hilton CJ (1993) Cyclic adenosine monophosphate promotes cell survival and retards apoptosis in a factor-dependent bone marrow-derived cell line. Exp Hematol 21:269–276PubMedGoogle Scholar
  74. 74.
    Mykhaylyk O, Zelphati O, Rosenecker J, Plank C (2008) siRNA delivery by magnetofection. Curr Opin Mol Ther 10:493–505PubMedGoogle Scholar
  75. 75.
    Wilhelm C, Gazeau F, Bacri JC (2002) Magnetophoresis and ferromagnetic resonance of magnetically labeled cells. Eur Biophys J 31:118–125PubMedCrossRefGoogle Scholar
  76. 76.
    Mykhaylyk O, Zelphati O, Hammerschmid E, Anton M, Rosenecker J, Plank C (2009) Recent advances in magnetofection and its potential to deliver siRNAs in vitro. Methods Mol Biol 487:111–146PubMedGoogle Scholar
  77. 77.
    Suzuki M, Mikami T, Matsumoto T, Suzuki S (1977) Preparation and antitumor activity of o-palmitoyldextran phosphates, o-palmitoyldextrans, and dextran phosphate. Carbohydr Res 53:223–229PubMedCrossRefGoogle Scholar
  78. 78.
    Snyder F, Stephens N (1959) A simplified spectrophotometric determination of ester groups in lipids. Biochim Biophys Acta 34:244–245PubMedCrossRefGoogle Scholar
  79. 79.
    Esbjorner EK, Oglecka K, Lincoln P, Graslund A, Norden B (2007) Membrane binding of pH-sensitive influenza fusion peptides. positioning, configuration, and induced leakage in a lipid vesicle model. Biochemistry 46:13490–13504PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2015

Authors and Affiliations

  • Olga Mykhaylyk
    • 1
  • Yolanda Sanchez-Antequera
    • 1
  • Dialechti Vlaskou
    • 1
  • Maria Belen Cerda
    • 2
  • Mehrdad Bokharaei
    • 3
  • Edelburga Hammerschmid
    • 1
  • Martina Anton
    • 1
  • Christian Plank
    • 4
  1. 1.Institute of Experimental OncologyKlinikum rechts der Isar der Technischen Universität MünchenMunichGermany
  2. 2.National Atomic Energy CommissionBuenos AiresArgentina
  3. 3.Faculty of Pharmaceutical SciencesThe University of British ColumbiaVancouverCanada
  4. 4.Institute of Experimental OncologyKlinikum rechts der Isar der Technischen Universität MünchenMunichGermany

Personalised recommendations